Zobrazeno 1 - 10
of 172
pro vyhledávání: '"JOCELYN GAL"'
Autor:
Tanguy Pace-Loscos, Jocelyn Gal, Sara Contu, Renaud Schiappa, Emmanuel Chamorey, Dorian Culié
Publikováno v:
BMC Bioinformatics, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background In the realm of biomedical research, the growing volume, diversity and quantity of data has escalated the demand for statistical analysis as it is indispensable for synthesizing, interpreting, and publishing data. Hence the need f
Externí odkaz:
https://doaj.org/article/139db4ae4f754569aaa79cea74486211
Autor:
Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, Caroline Hoffmann, Gilles Dolivet, Olivier Malard, Jérôme Fayette, Olivier Capitain, Sébastien Vergez, Lionel Geoffrois, Frédéric Rolland, Philippe Zrounba, Laurent Laccourreye, Esma Saada-Bouzid, Nicolas Aide, Valérie Bénavent, Jerzy Klijianenko, Constance Lamy, Elodie Girard, Sophie Vacher, Julien Masliah-Planchon, Leanne de Koning, Vincent Puard, Edith Borcoman, Marta Jimenez, Ivan Bièche, Jocelyn Gal, Christophe Le Tourneau
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase inhi
Externí odkaz:
https://doaj.org/article/71b235740be44697822692560686e4ae
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 816 (2024)
The conventional rules for anti-cancer drug development are no longer sufficient given the relatively limited number of patients available for therapeutic trials. It is thus a real challenge to better design trials in the context of new drug approval
Externí odkaz:
https://doaj.org/article/ef248f46de084aa8b441a9660e555f05
Autor:
Caroline Bailleux, David Chardin, Jean-Marie Guigonis, Jean-Marc Ferrero, Yann Chateau, Olivier Humbert, Thierry Pourcher, Jocelyn Gal
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 5136-5143 (2023)
Purpose: Meta-analyses failed to accurately identify patients with non-metastatic breast cancer who are likely to benefit from chemotherapy, and metabolomics could provide new answers. In our previous published work, patients were clustered using fiv
Externí odkaz:
https://doaj.org/article/816f939c016a42129efa98d1890845fc
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 38, Iss , Pp 71-76 (2023)
Purpose: To analyze long-term oncological outcome after 2nd conservative treatment (2ndCT) for patients with ipsilateral 2nd ipsilateral breast tumor event (2ndIBTE). Materials/methods: In this retrospective observational study (N°F20210402152843),
Externí odkaz:
https://doaj.org/article/7317cc3d03374c8c882c1f2b974e3c5c
Autor:
Marie-Eve Chand-Fouché, Claudine Colnard, Jocelyn Gal, Daniel Lam Cham Kee, Catherine Dejean, Matthieu Gautier, Julien Feuillade, Aurélia Mana, Yves Fouché, Yann Delpech, Magali Dejode, Jean-Pierre Gérard, Emmanuel Barranger
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 38, Iss , Pp 47-52 (2023)
Background and Purpose: Breast intra operative radiation therapy has been evaluated with different systems delivering 20–21 Gy with treatment times around 30 min. Papillon + TM Contact X-ray machine was designed to produce a 50 kVp beam with a high
Externí odkaz:
https://doaj.org/article/28ed8f926065458fb47fa824cc6519b8
Autor:
Jean-Michel Hannoun-Levi, Marie-Eve Chand-Fouche, Tanguy Pace-Loscos, Mathieu Gautier, Jocelyn Gal, Renaud Schiappa, Nina Pujol
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 37, Iss , Pp 64-70 (2022)
Purpose: To report the results of the Single Fraction Early Prostate Irradiation (SiFEPI) phase 2 prospective trial. Materials/Methods: The SiFEPI trial (NCT02104362) evaluated a single fraction of high-dose rate brachytherapy (HDB) for low- (LR) and
Externí odkaz:
https://doaj.org/article/ba481b83c50843eb84967432af6eff73
Publikováno v:
Pharmaceutics, Vol 16, Iss 2, p 211 (2024)
Artificial intelligence (AI) is progressively spreading through the world of health, particularly in the field of oncology. AI offers new, exciting perspectives in drug development as toxicity and efficacy can be predicted from computer-designed acti
Externí odkaz:
https://doaj.org/article/8950bdaf2f7d4fc3a5fc38e8bfee6352
Autor:
Delphine Marotte, Jocelyn Gal, Renaud Schiappa, Mathieu Gautier, Rabia Boulahssass, Marie-Eve Chand-Fouche, Jean-Michel Hannoun-Levi
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 35, Iss , Pp 104-109 (2022)
Purpose: To analyze the oncological outcome in elderly (>70 years) prostate cancer after high-dose rate brachytherapy (HDB) boost. Materials/methods: In this retrospective study, patients with intermediate (IR) and high-risk (HR) prostate cancer unde
Externí odkaz:
https://doaj.org/article/8071efa1a0ca4367b726ca8c89a6a5c1
Autor:
Jocelyn Gal, Caroline Bailleux, David Chardin, Thierry Pourcher, Julia Gilhodes, Lun Jing, Jean-Marie Guigonis, Jean-Marc Ferrero, Gerard Milano, Baharia Mograbi, Patrick Brest, Yann Chateau, Olivier Humbert, Emmanuel Chamorey
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 18, Iss , Pp 1509-1524 (2020)
Genomics and transcriptomics have led to the widely-used molecular classification of breast cancer (BC). However, heterogeneous biological behaviors persist within breast cancer subtypes. Metabolomics is a rapidly-expanding field of study dedicated t
Externí odkaz:
https://doaj.org/article/1231c5e493db4c508ef5a525afd36765